COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by North Lincolnshire CCG November 2012
|
|
- Melvyn Dixon
- 6 years ago
- Views:
Transcription
1 Drug, Treatment, Device name Omalizumab (Xolair; Novartis) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by North Lincolnshire CCG November 2012 Licensed indication Omalizumab to treat chronic urticaria is an unlicensed indication. Xolair is licensed as add-on therapy to improve asthma control in adult and adolescent patients (12 years of age and above) with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 < 80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist. Xolair treatment should only be considered for patients with convincing IgE mediated asthma. Cost per patient (at recommended dose) The licensed dose is dependent on body weight and baseline serum IgE. Patients with a body weight or baseline IgE outside the tables presented in the SmPC should not be given omalizumab as there is insufficient data to allow dosage recommendations. Drug Doses SmPC Cost Omalizumab 75mg every 4 weeks 1, Omalizumab 225mg every 2 weeks 9, Omalizumab 600mg every 2 weeks 26, Resource impact on population None identified as not routinely commissioned. Recommendation to Not Routinely Commission When is funding appropriate? Omalizumab is not recommended for the management of chronic urticaria due to the limited evidence of clinical and absence of cost effectiveness for this indication. Any requests should be made to the IFR Panel. Clinical and cost effectiveness evidence Background Urticaria is a condition characterised by localized or wide spread pruritic wheals that typically exist for no more than 24 hours. By definition acute urticaria lasts no longer than six weeks, whereas chronic urticaria lasts longer, often several years. Chronic urticaria can be classified into several subtypes but these may have overlapping features. Chronic urticaria that has no detectable cause is termed chronic idiopathic urticaria. Autoimmune urticaria is not a welldefined term but it is generally recognized that those with autoimmune urticaria have anti-igg antibodies against the high-affinity IgE receptor on mast cells and basophils or directly to IgE antibodies. Autoimmune urticaria affects about one third of all patients with chronic urticaria. 1
2 Omalizumab is a recombinant humanised monoclonal antibody that blocks the high affinity Fc receptor of IgE. Omalizumab has been approved for the treatment of moderate to severe asthma. There is evidence in the form of case reports and two small phase 2 clinical trials that show omalizumab may be of benefit in some patients with chronic urticaria. This policy has been drafted following a series of individual funding requests submitted to the PCT. British Association of Dermatologists therapy guidelines Guidelines for evaluation and management of urticaria in adults and children Grattan et al. British Journal of Dermatology 2007, 157, p /urticaria%20and%20angiodema%20(2007).pdf 1 Urticaria can usually be classified on the clinical presentation without extensive investigation. The weals of physical urticaria usually last less than 1 h (except delayed pressure urticaria) whereas those of ordinary urticaria typically last from 2 to 24 h. Urticarial vasculitis should be sought by skin biopsy if weals last longer. 2 Urticaria often remains idiopathic after allergic, infectious, physical and drug-related causes have been excluded as far as possible. At least 30% of patients with the ordinary presentation of chronic urticaria appear to have an autoimmune aetiology. The autologous serum skin test is a reasonably sensitive and specific marker for histamine-releasing autoantibodies in this group. 3 Advice on general measures and information can be helpful for most patients with urticaria, especially if an avoidable physical or dietary trigger can be identified. Over 40% of hospitalized patients with urticaria show a good response to antihistamines, which are the mainstay of therapy. 4 It has become common practice to increase the dose of second- generation H1 antihistamines above the manufacturer s licensed recommendation for patients when the potential benefits are considered to outweigh any risks. 5 Combinations of nonsedating H1 antihistamines with other agents, such as H2 antihistamines, sedating antihistamines at night or the addition of antileukotrienes, can be useful for resistant cases. 6 Oral corticosteroids should be restricted to short courses for severe acute urticaria or angiooedema affecting the mouth, although more prolonged treatment may be necessary for delayed pressure urticaria or urticarial vasculitis. 7 Immunomodulating therapies for chronic autoimmune urticaria should be restricted to patients with disabling disease who have not responded to optimal conventional treatments. The guidelines only make one mention of omalizumab with reference of a successful treatment of one patient with cold urticaria. EAACI/GALEN/EDF/WAO guideline: management of urticaria Zuberbier T et al Allergy 2009: 64: (EAACI = European Academy of Allergology and clinical immunology; GALEN = Global Allergy and Asthma European Network; EDF = European Dermatology Forum; WAO = World Allergy Organisation). ttp://eaaci.net/attachments/1252_eaaci%20position%20paper%20guideline.pdf 2
3 Non sedating-antihistamine (nsah) If symptoms persist after 2 weeks nsah (up to 4x) Comments on the above algorithm If symptoms persist after 1-4 weeks Add Leukotriene antagonist or change nsah Exacerbation: Systemic steroid (for 3-7 days) If symptoms persist after 1-4 weeks Add Ciclosporin A, H2-antihistamine, dapsone, omalizumab Exacerbation: Systemic steroid (for 3-7 days) First line: High quality evidence Very good safety profile Very good evidence for efficacy Second line: Low quality of evidence Good evidence for efficacy Third Line: Very low quality evidence Low to medium cost Insufficient or no evidence for efficacy In high quality RCT Fourth Line Ciclosporin Medium to high cost Moderate safety profile Moderate level of evidence for efficacy H2-antihistamine Very low level of evidence for efficacy Dapsone 3
4 Medium level of side effects Low level of evidence for efficacy Anti-IgE (omalizumab) High cost Low level evidence for good efficacy It states that omalizumab has been shown to be effective in selected patients with chronic spontaneous urticaria, cholinergic uritcaria, cold urticaria and solar urticaria but larger double blind placebo controlled trials are needed to confirm these results. Omalizumab for Chronic Urticaria: A Case Series and Overview of the Literature Ivyansky I et al Case reports in Dermatology 2012;4: This was a case series of 19 patients (14 were female). The mean age was 36 years for females and 49 for males. The mean duration of disease at initiation of omalizumab in the sample was 21 months for females and 24 months for males. 63% of patients were classified as having chronic idiopathic urticaria, 32% of patients had chronic autoimmune urticaria and 5% had delayed pressure urticaria. Patients had been treated with anti-histamines, steroids, azathioprine and 6 with anti-tnfs. All patients received a dose of omalizumab of 150mg every 2 weeks. In total, 11 patients (58%) experienced almost complete or complete resolution of symptoms and 5 (26%) patients experienced partial resolution and 3 (16%) patients had not benefit. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase Maurer et al. Journal of allergy and Clinical immunology Vol.128 Iss1; p , July 2011 This was a multicenter, randomised, double blind, placebo controlled study patients with chronic urticaria with IgE autoantibodies against thryoperoxidase who had persistent symptoms (wheels and pruritis) despite standard antihistamine therapy. 49 Patients were randomised to receive either placebo (22) or omalizumab (27) (dose dependent on weight and IgE level) every 2 to 4 weeks for a total of 24 weeks. Patients were aged between 18 to 70 years with a clinical diagnosis of moderate to severe chronic urticaria. This was defined as persistent symptoms for more than 6 weeks despite taking maximum dose of antihistamine therapy, a total IgE level of between IU/ml within the last 3 months prior to randomization, and a weekly urticaria activity score of 10 or more. The primary end point was the change from baseline in mean weekly urticaria activity score after 24 weeks of treatment, as calculated from patients diaries. A total of 42 patients completed the study. At baseline the mean UAS were 24.6+/-7.4 and 21.3+/-7.6 for the omalizumab and placebo group respectively. At week 24, patients demonstrated a mean reduction in the weekly urticaria activity score of 17.8 with omalizumab and 7.9 with placebo (p=0.089). Complete protection from wheel development was observed in 19 (70.4%) patients in the omalizumab group compared with only 1 (4.5%) patient in placebo group. According to patients global assessments of symptoms, 59% of those in the omalizumab group reported to be symptom free at the end of the study compared to 14% in the placebo group. 4
5 The rate of adverse events with similar in both groups. The most frequent adverse events were diarrhoea, nasopharynigitis and headache. A randomised, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. Saini S J allergy Clin Immunol Sep; 128 (3): This study aimed to evaluate the efficacy and safety of omalizumab in patients with chronic idiopathic urticaria who remain symptomatic despite concomitant H(1)- antihistamine therapy. this was a phase II, prospective, double blind, placebo-controlled, dose-ranging study to assess omalizumab in patients aged 12 to 75 years in the USA and Germany with UAS over 7 days of 12 or greater despite antihistamine therapy. Patients received either 75, 300 or 600mg of omalizumab or placebo. The primary end point was change from baseline to week 4 in UAS7. Patients were followed up for an additional 12 weeks to monitor safety. 90 patients were recruited to the study. Both the 300mg omalizumab group (-19.9 vs -6.9, p<0.001) and the 600mg group omalizumab group (-14.6 vs -6.9, p=0.047) showed greater improvement versus the placebo group in UAS7. no meaningful difference was observed for the 75mg omalizumab group. Adverse events were similar across treatment groups. Treatment of chronic autoimmune urticaria with omalizumab Kaplan et al J Allergy Clin Immunol. Vol.122;no.3; Approximately 45% of patients with chronic urticaria have an IgG autoantibody directed to the high affinity IgE receptor leading to cutaneous mast cell and basophil activation. This study aimed to investigate the efficacy of omalizumab in patients with CAU symptomatic despite antihistamine therapy. Patients with chronic urticaria were defined as having symptoms for at least 6 weeks, with hives present most days of the week despite antihistamines. A total serum IgE <700IU/ml was required to enter the study. 12 patients were recruited to the study and received placebo for 4 weeks followed by omalizumab every 2 to 4 weeks (dose dependent on weight and IgE level)for 16 weeks. Primary endpoint was change from baseline to the final 4 weeks of omalizumab in mean Urticaria activity score (scale 0-9). Changes in rescue medication and quality of life was also assessed. Mean UAS declined significantly from baseline to the end of the study (7.5+/-1.78 to 2.66+/-3.31, /-2.86, p=0.0002). 7 patients achieved complete symptom resolution. In 4 patients, mean UAS decreased but Urticaria persisted. 1 patient did not respond. Rescue medication was reduced and quality of life improved and no adverse effects were reported. It concluded that omalizumab may be useful for treatment of patients with CAU not responsive to antihistamines. Further studies should be performed to confirm these findings in CAU and to assess efficacy in other forms of chronic urticaria. Points for consideration Omalizumab is not licensed for the treatment of chronic urticaria and the published data supporting the use is limited to 2 small phase 2 clinical trials and case reports. Guidelines from the British Association of Dermatologists on the management of urticaria do not include omalizumab as part of its recommendations. 5
6 EAACI/GALEN/EDF/WAO guideline: management of urticaria 2009 does include omalizumab as a treatment option when all other standard treatments have failed. Studies have shown that omalizumab may be a useful treatment option for patients with chronic autoimmune urticaria but long term efficacy is lacking Place in therapy relative to available treatments N/A Health gains Studies have shown that omalizumab may be a useful treatment option for patients with chronic autoimmune urticaria but long term efficacy is lacking. Patient monitoring / impact Patient safety / pharmacovigilance Monitoring criteria Urticaria activity score DLQI score Adverse effects When to stop treatment Severe adverse effects Response assessed at 12 weeks and treatment discontinued in those patients who have not shown an adequate response to treatment based on a full clinical assessment. Who prescribes? It not recommended for commissioning. SPECIFICATION DATE, REVIEW DATE, AND LEAD NAME/JOB TITLE Origin Date: October 2012 Originator: TAG Review Date: November 2014 Reviewer: Christopher Ranson, Clinical TAG Recommendation Date: November 2012 Effectiveness Pharmacist Impact on individual clinical commissioning groups CCG Population Cost Impact Vale of York 337,500 Harrogate and Rural District 160,100 Scarborough & Ryedale 118,000 Hambleton, Richmondshire & Whitby 141,600 East Riding of Yorkshire 320,642 Hull 295,987 North Lincolnshire 168,400 North East Lincolnshire 167,200 6
omalizumab 150mg solution for injection (Xolair ) SMC No. (1017/14) Novartis Pharmaceuticals UK Ltd
omalizumab 150mg solution for injection (Xolair ) SMC No. (1017/14) Novartis Pharmaceuticals UK Ltd 05 December 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationXolair. Xolair (omalizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.02 Subject: Xolair Page: 1 of 6 Last Review Date: March 18, 2016 Xolair Description Xolair (omalizumab)
More informationXolair. Xolair (omalizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.02 Subject: Xolair Page: 1 of 7 Last Review Date: September 15, 2016 Xolair Description Xolair (omalizumab)
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Omalizumab Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 6 References... 7 Effective Date... 3/15/2018 Next
More informationThe management of chronic urticaria in primary care for adults and children
The management of chronic urticaria in primary care for adults and children September Version 2.0 This supersedes version 1.0 Review due in September 2019 Document location DOCUMENT CONTROL Copies of this
More information2012/12/5. Principle of the management of urticaria. The efficacy of systemic steroid on urticaria depends of subtypes urticaria
6 December 2012: 13:3015:00 G.04 (HICC) The Hyderabad International Convention Centre (HICC) in Hyderabad, India WISC 2012; WAO International Scientific Conference Postgraduate Course 16: URTICARIA & ANGIOEDEMA
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION OMALIZUMAB (Xolair Novartis Pharmaceuticals Canada Inc.) Indication: Chronic Idiopathic Urticaria Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that omalizumab
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationThe proposal is to add text/statements in red and to delete text/statements with strikethrough: POLICY
Omalizumab DESCRIPTION Omalizumab is a recombinant DNA-derived humanized IgG1κ monoclonal antibody which selectively binds to immunoglobulin E (IgE). High serum levels of IgE are found in individuals with
More informationXolair (omalizumab) Limitation of Use: Xolair is not indicated for treatment of other forms of urticaria.
Xolair (omalizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective Date: 12/01/2017TBD POLICY A. INDICATIONS The indications below
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationLocal Omalizumab Treatment Protocol (For children 6 to <12 years of age)
Local Omalizumab Treatment Protocol (For children 6 to
More informationxx Xolair 150 MG SOLR (GENENTECH)
Omalizumab NDC CODE(S) 50242-0040-xx Xolair 150 MG SOLR (GENENTECH) DESCRIPTION Omalizumab is a recombinant DNA-derived humanized IgG1κ monoclonal antibody which selectively binds to immunoglobulin E (IgE).
More informationManagement of Chronic Idiopathic Urticaria
9/3/216 Management of Chronic Idiopathic Urticaria Brian Berman, M.D., Ph.D. Professor Emeritus of Dermatology and Dermatologic Surgery, University of Miami Co-Director Center for Clinical and Cosmetic
More informationMast Cell Mediators. Updates on Chronic Urticaria 11/1/2016. Urticaria: What happens in the skin?
Urticaria: What happens in the skin? Updates on Chronic Urticaria Kent Woo, MD (USA) Allergy/Immunology Internal Medicine C A U S E MC, mast cell IgE Fc eri MC Release of Mediators Activation Vasodilation
More informationPredicting Response to Omalizumab in Chronic Urticaria Based on Biomarkers
Predicting Response to Omalizumab in Chronic Urticaria Based on Biomarkers Authors: *Misbah Noshela Ghazanfar, 1 Simon Francis Thomsen 1,2 1. Department of Dermatology, Bispebjerg Hospital, Copenhagen,
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationand will be denied as not medically necessary** if not met. This criterion only applies to the initial
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationomalizumab 150mg powder and solvent for injection (Xolair ) No. (259/06) Novartis Pharmaceuticals UK Ltd.
Scottish Medicines Consortium Re-Submission omalizumab 150mg powder and solvent for injection (Xolair ) No. (259/06) Novartis Pharmaceuticals UK Ltd. 8 December 2006 The Scottish Medicines Consortium (SMC)
More informationU N I V E R S I T Ä T S M E D I Z I N B E R L I N
U N I V E R S I T Ä T S M E D I Z I N B E R L I N Disclosure of Significant Relationships with Commercial Companies and Organizations Funding of Research by Deutsche Forschungsgemeinschaft (DFG), EU (FP7,
More information3302: Therapy Options for Patients with Anti-Histamine Resistant Chronic Urticaria
3302: Therapy Options for Patients with Anti-Histamine Resistant Chronic Urticaria Javed Sheikh, M.D. FAAAI Department of Allergy & Clinical Immunology Kaiser Permanente Los Angeles Medical Center Disclosure
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Drug, Treatment, Device name Co-careldopa 2000mg/500mg intestinal gel (Duodopa, Solvay Pharmaceuticals)
More informationClinical Policy Title: Omalizumab for the treatment of chronic idiopathic urticaria
Clinical Policy Title: Omalizumab for the treatment of chronic idiopathic urticaria Clinical Policy Number: 18.02.07 Effective Date: April 1, 2016 Initial Review Date: January 20, 2016 Most Recent Review
More informationXOLAIR (omalizumab) Prior Authorization
MP9309 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below May only be prescribed by Allergy, Pulmonary, Immunology or Dermatology specialists
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 03/03/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Xolair (omalizumab) Commercial HMO/PPO/CDHP HMO/PPO/CDHP: Rx
More informationUrticaria. Appearance. Epidemiology [1] Aetiology [2]
Page 1 of 5 View this article online at: patient.info/doctor/urticaria-pro Urticaria Urticaria, otherwise known as hives, is an itchy red blotchy rash resulting from swelling of the superficial part of
More informationOmalizumab as monotherapy for refractory chronic idiopathic urticaria: A prospective noncomparative open study from Kuwait
ORIGINAL ARTICLE Omalizumab as monotherapy for refractory chronic idiopathic urticaria: A prospective noncomparative open study from Kuwait Rachna Jagia, MD, DNB, Tarek Omar, MD, Ahmed Al-Haddad, MD, Yashpal
More informationO R I G I N A L A R T I C L E Eur Ann Allergy Clin Immunol Vol 49, N 5, , 2017
O R I G I N A L A R T I C L E Eur Ann Allergy Clin Immunol Vol 49, N 5, 22-224, 217 T. Boonpiyathad, A. Sangasapaviliya Hydroxychloroquine in the treatment of anti-histamine refractory chronic spontaneous
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
XOLAIR (omalizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationOmalizumab (Xolair) NHLBI normal ranges by age for FEV 1/FVC 8-19 years of age 85%; years of age 80%;
DRAFT Medical Coverage Policy Injectable Agents for Asthma and Chronic Idiopathic Urticaria Fasenra, Nucala, Xolair, Cinqair EFFECTIVE DATE: 03 01 2018 POLICY LAST UPDATED: 03 20 2018 OVERVIEW This policy
More informationTechnology appraisal guidance Published: 8 June 2015 nice.org.uk/guidance/ta339
Omalizumab for previously treated chronic spontaneous urticaria Technology appraisal guidance Published: 8 June 2015 nice.org.uk/guidance/ta339 NICE 2018. All rights reserved. Subject to Notice of rights
More informationFIT Board Review Corner April 2017
FIT Board Review Corner April 2017 Welcome to the FIT Board Review Corner, prepared by Tammy Peng, MD, and Amar Dixit, MD, senior and junior representatives of ACAAI's Fellows-In-Training (FITs) to the
More informationPharmacy Medical Policy IgE Receptor Binding Inhibitors
Pharmacy Medical Policy IgE Receptor Binding Inhibitors Table of Contents Policy: Commercial Policy History Endnotes Policy: Medicare Information Pertaining to All Policies Forms Coding Information References
More informationUrticaria is a common, heterogeneous group of disorders
SYMPOSIUM REPORT SUPPLEMENT A Summary of the New International EAACI/GA 2 LEN/EDF/ WAO Guidelines in Torsten Zuberbier, MD Abstract: is a heterogeneous group of disorders, especially acute and angiooedema
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Xolair) Reference Number: CP.CPA.298 Effective Date: 11.16.16 Last Review Date: 11.15.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationOmalizumab: what benefits should we expect?
ejd150659 INVESTIGATIVE REPORT Omalizumab: what benefits should we expect? Ana GIMÉNEZ-ARNAU 1 Manel VELASCO 2 Jose Carlos ARMARIO HITA 3 Moises LABRADOR-HORRILLO 4 Juan Francisco SILVESTRE SALVADOR 5
More informationBOLSTRAN Injection (Omalizumab)
Published on: 27 Feb 2017 BOLSTRAN Injection (Omalizumab) Composition Active Substance Omalizumab is a humanized monoclonal antibody manufactured from a mammalian cell line. One vial of BOLSTRAN 150 mg
More informationSwiss Expert Opinion on the Management of Chronic Spontaneous Urticaria
Swiss Expert Opinion on the Management of Chronic Spontaneous Urticaria P. Schmid-Grendelmeier 1, B. Ballmer-Weber 2, J. Faeh 3, G. Ferrari 4, J. Grabbe 5, O. Hausmann 6, A. Helbling 7, W. Hötzenecker
More informationOmalizumab for previously treated chronic spontaneous urticaria
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Appraisal consultation document Omalizumab for previously treated chronic spontaneous urticaria The Department of Health has asked the National Institute
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More informationCHRONIC URTICARIA; IT S MORE THAN JUST ANTIHISTAMINES!
CHRONIC URTICARIA; IT S MORE THAN JUST ANTIHISTAMINES! Randy D. Danielsen, PhD, PA, DFAAPA Dean & Professor Arizona School of Health Sciences A.T. Still University Ûr tĭ-kâr ē-ә Urticaria is characterized
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: xolair_omalizumab 9/2003 11/2017 11/2018 11/2017 Description of Procedure or Service Asthma is a chronic
More informationTRANSPARENCY COMMITTEE OPINION. 13 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 January 2010 XOLAIR 150 mg, powder and solvent for solution for injection Box containing 1 x 150 mg vial + 1 x
More informationPerspectives in Primary Care: Evaluating and Managing Patients With Chronic Urticaria
Perspectives in Primary Care: Evaluating and Managing Patients With Chronic Urticaria Please complete the preassessment located in your meeting handout before the program begins. Sponsorship and Support
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Xolair (omalizumab) Policy Number: MP-051-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationOmalizumab vs. Mepolizumab for Asthma Patients: How to Decide. Indications
vs. for Asthma Patients: How to Decide Indications Asthma is indicated for patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity
More informationManaging urticaria in primary care
Managing urticaria in primary care Tidman MJ. Managing urticaria in primary care. Practitioner 2015;259(1779)25-28 Dr Michael J. Tidman MD FRCP (Ed) FRCP (Lond) Consultant Dermatologist, Department of
More informationLCD for Omalizumab (Xolair ) (L29240)
LCD for Omalizumab (Xolair ) (L29240) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD ID Number L29240 LCD Information
More informationEuropean Medicines Agency decision
EMA/463568/2010 European Medicines Agency decision P/133/2010 of 28 July 2010 on the refusal of a paediatric investigation plan and on the granting of a waiver for omalizumab, (Xolair) (EMEA-000735-PIP01-09)
More informationEverant.in/index.php/jmpr. Journal of Medical Practice and Review
Everant.in/index.php/jmpr Journal of Medical Practice and Review Real world Efficacy and Tolerance of Bepotastine, a new 2 nd generation antihistamine, in Pruritis and other symptoms associated with cutaneous
More information2. Does the patient have chronic urticaria? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Xolair (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationImmunomodulators: Anti-IgE mab. Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE
Immunomodulators: Anti-IgE mab Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE Objectives To explain the rationale behind IgE blockade To discuss which
More informationClinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date: Last Review Date: 08.17
Clinical Policy: (Xolair) Reference Number: ERX.SPA.141 Effective Date: 03.01.14 Last Review Date: 08.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationTechnology appraisal guidance Published: 24 April 2013 nice.org.uk/guidance/ta278
Omalizumab for treating severeere persistent allergic asthma Technology appraisal guidance Published: 24 April 2013 nice.org.uk/guidance/ta278 NICE 2018. All rights reserved. Subject to Notice of rights
More informationOmalizumab for Treating Chronic Spontaneous Urticaria: an Expert Review on Efficacy
Omalizumab for Treating Chronic Spontaneous Urticaria: an Expert Review on Efficacy and Safety Length: 3550 words (not including tables, figures and references) Keywords: Anti-IgE, Chronic Urticaria, Chronic
More informationAdd on therapy in asthma. Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes
Add on therapy in asthma Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes Programme Omalizumab Evidence and assessment Local Experience Dysfunctional breathing The other effective
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationChronic urticaria (CU) is a debilitating skin condition
Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria Ravi K. Viswanathan, M.D., Mark H. Moss, M.D., and Sameer K. Mathur, M.D., Ph.D. ABSTRACT Omalizumab has been shown
More informationABSTRACT. Keywords: Angioedema; Chronic spontaneous urticaria; Omalizumab; UAS7; Urticaria treatment; Wheal ORIGINAL RESEARCH
Dermatol Ther (Heidelb) (2018) 8:291 301 https://doi.org/10.1007/s13555-018-0240-7 ORIGINAL RESEARCH Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Xolair 75 mg powder and solvent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 75
More informationJapanese Guidelines for Diagnosis and Treatment of Urticaria in Comparison with Other Countries Michihiro Hide 1 and Takaaki Hiragun 1
Allergology International. 2012;61:517-527 DOI: 10.2332 allergolint.12-rai-0497 REVIEW ARTICLE Review Series: Advances in Consensus, Pathogenesis and Treatment of Urticaria and Angioedema Japanese Guidelines
More informationA Case Series Study of Eighty-Five Chronic Spontaneous Urticaria Patients Referred to a Tertiary Care Center
Treatment of Urticaria Ann Dermatol Vol. 26, No. 1, 2014 http://dx.doi.org/10.5021/ad.2014.26.1.73 ORIGINAL ARTICLE A Case Series Study of Eighty-Five Chronic Spontaneous Urticaria Patients Referred to
More informationUrticaria and Angioedema. Allergy and Immunology Awareness Program
Urticaria and Angioedema Allergy and Immunology Awareness Program 1 Urticaria and Angioedema Allergy and Immunology Awareness Program Urticaria Commonly known as hives, urticarial is an itchy rash with
More informationEffects of omalizumab treatment on serum cytokine concentrations of atopic patients with chronic spontaneous urticaria: a preliminary report
O R I G I N A L A R T I C L E S Eur Ann Allergy Clin Immunol Vol 49, N 4, 171-175, 217 A. Sellitto 1,3, U. De Fanis 1,4, A. Balestrieri 2, A. Savoia 2, C. Astarita 2, C. Romano 1 Effects of omalizumab
More informationHow to Successfully Manage Chronic Urticaria? & Tall Tales from Texas
How to Successfully Manage Chronic Urticaria? & Tall Tales from Texas David A. Khan, MD Professor of Medicine and Pediatrics Allergy & Immunology Program Director 1 Disclosures Honoraria/Speakers Bureau
More information4/12/18. Refractory Chronic Urticaria: When Omalizumab Fails. Objectives. Disclosures
Refractory Chronic Urticaria: When Omalizumab Fails David A. Khan, MD Professor of Medicine and Pediatrics Allergy & Immunology Program Director 1 Disclosures n Research Grants n NIH n Honoraria n UpToDate,
More informationClinical management of urticaria using omalizumab; the first licensed biologic therapy available for chronic spontaneous urticaria
SECTION 4 Clinical management of urticaria using omalizumab; the first licensed biologic therapy available for chronic spontaneous urticaria A. M. Giménez-Arnau 1, E.Toubi E 2, A. M. Marsland 3, M. Maurer
More informationU N I V E R S I T Ä T S M E D I Z I N B E R L I N
U N I V E R S I T Ä T S M E D I Z I N B E R L I N Chronic Urticaria: the role of mast cells and basophils Marcus Maurer Allergie-Centrum-Charité Department of Dermatology and Allergy Charité - Universitätsmedizin
More informationClinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date:
Clinical Policy: (Xolair) Reference Number: ERX.SPA.141 Effective Date: 03.01.14 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationPerspectives in Primary Care: Evaluating and Managing Patients with Chronic Urticaria
Saturday General Session Perspectives in Primary Care: Evaluating and Managing Patients with Chronic Urticaria Anne Marie Ditto, MD Associate Professor of Medicine Division of Allergy Immunology Northwestern
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Xolair 75 mg powder and solvent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 75
More informationBIOLOGICS IN ALLERGY 101 DR CLAUDIA GRAY ALLSA 2017
BIOLOGICS IN ALLERGY 101 DR CLAUDIA GRAY ALLSA 2017 DR CLAUDIA GRAY MBChB, FRCPCH (London), MSc (Surrey), Dip Allergy (Southampton), DipPaedNutrition(UK), PhD (UCT) Paediatrician and Allergologist, UCT
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Urticaria These podcasts are designed to give medical students an overview of key topics in pediatrics. The audio versions
More informationClinical Study Autologous Serum Skin Test as a Diagnostic Aid in Chronic Idiopathic Urticaria
ISRN Dermatology Volume 2013, Article ID 291524, 4 pages http://dx.doi.org/10.1155/2013/291524 Clinical Study Autologous Serum Skin Test as a Diagnostic Aid in Chronic Idiopathic Urticaria Hayder R. Al-Hamamy,
More informationAutologous serum skin test versus histamine release test in the diagnosis of Chronic autoimmune urticaria
ORIGINAL ARTICLE Autologous serum skin test versus histamine release test in the diagnosis of Chronic autoimmune urticaria Al-Sadat Mosbeh, 1 MD, Ibrahim G. Ramadan, 2 MD, Abdelaleem Elgendy, 3 MD 1 Department
More informationREFERRAL GUIDELINES - SUMMARY
Clinical Immunology & Allergy Unit LEEDS TEACHING HOSPITALS NHS TRUST REFERRAL GUIDELINES - SUMMARY THESE GUIDELINES ARE DESIGNED TO ENSURE THAT PATIENTS REQUIRING SECONDARY CARE ARE SEEN EFFICIENTLY AND
More informationPharmacy Management Drug Policy
SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes
More informationPolicy Number: PHARMACY T2 Effective Date: December 1, 2017
XOLAIR (OMALIZUMAB) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 047.25 T2 Effective Date: December 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationThey re Scratching and You re Scratching Your Head: An Approach to the Diagnosis and Management of Acute and Chronic Urticaria
They re Scratching and You re Scratching Your Head: An Approach to the Diagnosis and Management of Acute and Chronic Urticaria Adelle R. Atkinson, MD, FRCPC Sea Courses May/June 2017 Copyright 2017 by
More informationEffectiveness of omalizumab in a patient with a life-threatening episode of bronchospasm and larynx angioedema after exposure to house dust
Case report Effectiveness of omalizumab in a patient with a life-threatening episode of bronchospasm and larynx angioedema after exposure to house dust Izabela Kupryś-Lipińska, Paulina Korczyńska, Damian
More informationXOLAIR (omalizumab) DRUG POLICY. Policy Number: 2014D0033H Effective Date: 9/1/2014. Related Medical or Drug Policies: None.
DRUG POLICY XOLAIR (omalizumab) Policy Number: 2014D0033H Effective Date: 9/1/2014 Table of Contents Page Related Medical or Drug Policies: None COVERAGE RATIONALE... 1 BENEFIT CONSIDERATIONS... 4 CLINICAL
More informationPolicy Effective 4/1/2018
Corporate Medical Policy Interleukin-5 Antagonists Notification File Name: Origination: Last CAP Review: Next CAP Review: Last Review: interleukin_5_antagonists 2/2016 11/2017 11/2018 2/2018 Policy Effective
More informationCenters. Austria (2), Germany (5), Belgium (1), Netherlands (1), Denmark (1), Slovenia (1)
Study CS-BM32-003 Sponsor Biomay Protocol title Phase IIb study on the safety and efficacy of BM32, a recombinant hypoallergenic vaccine for immunotherapy of grass pollen allergy Clinical trial phase Phase
More informationINVESTIGATIONS & PROCEDURES IN PULMONOLOGY. Immunotherapy in Asthma Dr. Zia Hashim
INVESTIGATIONS & PROCEDURES IN PULMONOLOGY Immunotherapy in Asthma Dr. Zia Hashim Definition Involves Administration of gradually increasing quantities of specific allergens to patients with IgE-mediated
More informationHCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
More informationALLERGIC RHINITIS AND ASTHMA :
ALLERGIC RHINITIS AND ASTHMA : from the Link to Emerging Therapies Allergic rhinitis and asthma are both chronic heterogeneous disorders, with an overlapping epidemiology of prevalence, health care costs
More informationEosinophilic Esophagitis. Kristine J. Krueger M.D. June 2014
Eosinophilic Esophagitis Kristine J. Krueger M.D. June 2014 A Most Interesting Patient 36 year old self employed tree surgeon with long standing history of intermittent dysphagia and atypical GERD, NOT
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice)
Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice) This drug has been reviewed because it is a product that may be prescribed in primary
More informationAutologous Serum Skin Test in Chronic Idiopathic Urticaria: Prevalence, Correlation and Clinical Implications
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2006) 24: 201-206 Autologous Serum Skin Test in Chronic Idiopathic Urticaria: Prevalence, Correlation and Clinical Implications Kanokvalai Kulthanan, Sukhum
More informationNot available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationAllergic Conditions in Sports. Seth Smith, MD, CAQ-SM, PharmD TPC Course February 7, 2016
Allergic Conditions in Sports Seth Smith, MD, CAQ-SM, PharmD TPC Course February 7, 2016 Goals and Objectives Describe diagnosis and management of exercise-induced bronchospasm/bronchoconstriction (EIB)
More informationXolair (omalizumab injection for subcutaneous [SC] use)
Xolair (omalizumab injection for subcutaneous [SC] use) Policy Number: 5.02.503 Last Review: 10/2017 Origination: 8/2003 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationMEDICAL POLICY I. POLICY. POLICY TITLE POLICY NUMBER OMALIZUMAB (XOLAIR ) MP-2.123
Original Issue Date (Created): May 3, 2004 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY. Note: Initial Authorization If the patient has been maintained
More information